Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 99   

Articles published

LGND 97.65 -1.28 (-1.29%)
price chart
Ligand Pharmaceuticals Inc Blair William & CoIl Bought New Stake
Blair William & CoIl has filled a SC 13G/A form regarding Ligand Pharmaceuticals Inc 98.60 0.00 % . Filing Link: 000114420415040828.
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces that company ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) opened trading today as $98.60 and is trading in the range of 96.13-98.66 today. Ligand's current market cap stands at $1.94 billion.
Cantor Fitzgerald Recommendation on Ligand Pharmaceuticals Incorporated ...  Insider Trading Report
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
LIGAND PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Related articles »  
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : Matthew W ...
Ligand Pharmaceuticals Inc (LGND): Matthew W Foehr , President and COO of Ligand Pharmaceuticals Inc sold 12,500 shares on Jun 26, 2015.
Analysts' Recent Ratings Updates for Ligand Pharmaceuticals (LGND)  sleekmoney
Insider Selling: Matthew W. Foehr Sells 12500 Shares of Ligand ...  The Legacy
Ligand Pharmaceuticals Inc (NASDAQ:LGND) close to 52-week high, short ...
Ligand Pharmaceuticals Inc (NASDAQ:LGND) (TREND ANALYSIS) shares were traded with a significant increase in volume. The stock closed last trading session at $96.17, up by 0.4%, with a volume of 798,531 shares against an average volume for the last ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a Hold: Cantor Fitzgerald  Markets.co
Weekly Research Analysts' Ratings Updates for Ligand Pharmaceuticals (LGND)  Dakota Financial News
Company Update (NASDAQ:LGND): FDA Approves Ligand Pharmaceuticals Inc ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta� (eltrombopag), a Novartis product, for the treatment of children six years and older with chronic ...
Drug co-developed by Ligand gets new application  San Diego Source (subscription)
FDA Approves Promacta� for New Pediatric Chronic Immune Thrombocytopenia ...  PharmiWeb.com (press release)
Melanie Herman an Insider in Ligand Pharmaceuticals Inc. (NASDAQ:LGND ...
A report filed with the Security and Exchange Commission on 11/06/2015 made public that Melanie Herman, the Interim CFO of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 98.60 0.00 % , professional & scientific & and technical services's company sold ...
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : John L ...  Insider Trading Report
Earnings in Focus: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is expected to post quarterly earnings on 2015-08-03. Investors will be eagerly eyeing the number the company reports compared to the earnings per share that brokers are predicting. Sell-side firms are ...
Matthew Foehr Unloaded 23046 Shares of Ligand Pharmaceuticals Inc ...
The President and COO of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 98.93 +0.33 0.33% and firm's insider Matthew Foehr made a sale of 23,046 shares of the firm based on the price of stock which is $96.5 per each share.
Ligand Pharmaceuticals COO Sells $2222786.70 in Stock (LGND)  sleekmoney
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Stock a Sell after Jason ...
The insider Jason Aryeh who is director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 100.86 +4.06 4.19% sold 9,240 shares of the public firm having a market value of $807,047 USD at an average $87.3 per share.
Ligand Pharmaceuticals Inc (LGND) Insider Selling : Jason Aryeh Sells 9240 ...  Money Flow Index
Active Watch List: Advaxis, Inc. (NASDAQ:ADXS), Ligand Pharmaceuticals ...  Stock Transcript